---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-027531"
form_type: "8-K"
ticker: "MDAI"
cik: "0001833498"
company_name: "Spectral AI, Inc."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-23T23:57:44.760624+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spectral AI reports FY2024 R&D revenue $29.6M; net loss $(15.3)M; plans FDA submission by Q2 2025

## Summary
- FY2024 R&D revenue $29.6M (+63.5% YoY); net loss $(15.3)M ($(0.85)/share) vs $(20.9)M in FY2023.
- Burn Validation Study: DeepView sensitivity 86.6% (image-wise) vs 40.8% for burn physicians; FDA De Novo submission planned by Q2 2025.
- Cash $5.2M at Dec 31, 2024; raised $11.2M in Q1 2025 via $8.5M debt & $2.7M equity; FY2025 revenue guidance ~$21.5M.
- CFO Vincent Capone amended employment: base salary $440k, bonus up to $250k; 100k RSUs vested, 75k stock options granted.
- Spin-off of Spectral IP into public company expected by end of Q2 2025; warrants repriced from $11.50 to $2.75.

## SEC filing metadata
- accession: 0001213900-25-027531
- form_type: 8-K
- ticker: MDAI
- cik: 0001833498
- company_name: Spectral AI, Inc.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833498/000121390025027531/0001213900-25-027531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833498/000121390025027531/ea0236475-8k_spectral.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-027531
- JSON: https://secwatch.observer/filing/0001213900-25-027531.json
- Plain text: https://secwatch.observer/filing/0001213900-25-027531.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.